News

STAT2d
Pharmalittle: We’re reading about a Merck shot for RSV, a lawsuit over an Arkansas PBM law, and more
Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...
Fierce Pharma3d
Feeling RSV heat from Merck, Sanofi lays out early supply plans for Beyfortus
One day before the potential FDA approval of a rival respiratory syncytial virus (RSV) monoclonal antibody from Merck & Co., ...
New antibody shot could help protect babies from RSV
A newly approved shot could soon help protect babies from respiratory syncytial virus (RSV), the top cause of hospitalization ...
Newly approved therapy could offer another option for protecting infants from RSV, a common infection that can be deadly
The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.
Fierce Pharma3d
Merck scores FDA nod for Enflonsia, setting up RSV market battle vs. Sanofi and AstraZeneca's Beyfortus
Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...
pharmaphorum3d
Sanofi starts shipping RSV drug early as rival nears market
Clesrovimab has been held up by MSD (known as Merck & Co in the US and Canada) as offering simpler dosing and better clinical ...